Combination therapy comprising Fas axis antagonist and T-reg cell depleting agent antagonist for treatment of cancer

By combining Fas axis antagonists in anti-CD25 antibody therapy, the problem of low response rate and tumor recurrence in poor immunogenic models was solved, and better immune response maintenance and tumor prevention effects were achieved.

CN119095621APending Publication Date: 2024-12-06F HOFFMANN LA ROCHE & CO AG +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380036238.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-26
Filing Date
2023-04-26
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing anti-CD25 antibody therapies have low response rates in some mouse models with poor immunogenicity and are not effective in tumor recurrence, making it difficult to effectively prevent tumor recurrence and improve patient survival.

Method used

In combination with Treg cell depletion therapy, such as anti-CD25 antibodies and anti-FasL antibodies, are administered separately, simultaneously or sequentially to enhance the immune response and prevent tumor recurrence.

Benefits of technology

By maintaining a high Teff/Treg cell ratio, it inhibits Fas-mediated death of activated Teff cell, prolongs patient survival and prevents tumor recurrence, significantly improving the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095621A_ABST
    Figure CN119095621A_ABST
Patent Text Reader

Abstract

The present disclosure relates to a combination of a Fas axis antagonist, such as an anti-FasL antibody, with a Treg cell depletion therapy, such as an anti-CD25 antibody, and optionally a cancer vaccine, for the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a combination of a Fas axis antagonist and Treg cell depletion therapy for treating cancer. Background Art

[0002] Depletion of regulatory T cells (Treg) using anti-CD25 antibodies has been shown to be effective in various cancer mouse models, for example, see WO2017 / 174331, WO2018 / 167104, WO2019 / 175222, and Solomon I et al, Nature Cancer, vol 1, p1153-1166 (2020). However, it was found that in some mouse models with poor immunogenicity, the response rate was low, and in some cases only a partial response was achieved in reducing tumor growth.

[0003] Combination therapy for cancer treatment consisting of an anti-CD25 Treg depleting antibody and a genetically modified GM-CSF-secreting tumor vaccine (GVAX) has been shown to improve therapeutic efficacy in such mouse models in terms of tumor size and mouse survival. However, after a partial response to this combination therapy, subsequent tumor recurrence has been observed in some cases.

[0004] Therefore, although current anti-CD25 antibody-based therapies have been shown to be effective in the initial treatment of cancer, there remains a need to provide further treatment options that can help prevent tumor recurrence and further improve patient survival. Summary of the invention

[0005] The present invention relates to a combination of Treg cell depletion therapy and a Fas axis binding antagonist, and the combination is used for treating cancer.

[0006] The present inventors have discovered that the combination of a Fas axis antagonist (eg, anti-FasL antibody) with a Treg cell depletion therapy (eg, anti-CD25 antibody) and an optional cancer vaccine (eg, GVAX) provides a cancer treatment regimen that reduces the likelihood of tumor recurrence and improves patient survival.

[0007] Therefore, one aspect of the present invention provides a combination of Treg cell depletion therapy and Fas axis antagonist for treating cancer. Treg cell depletion therapy and Fas axis antagonist are administered separately, simultaneously or sequentially.

[0008] One aspect of the present invention provides a combination of an anti-CD25 antibody and an anti-FasL antibody for use in treating cancer. The anti-CD25 antibody and the anti-FasL antibody are administered separately, simultaneously or sequentially.

[0009] Another aspect of the present invention provides Treg cell depletion therapy (eg, anti-CD25 antibody) for treating cancer, wherein the Treg cell depletion therapy is used in combination with a Fas axis antagonist (eg, anti-FasL antibody).

[0010] Another aspect of the present invention provides a Fas axis antagonist (eg, anti-FasL antibody) for use in treating cancer, wherein the Fas axis antagonist is used in combination with Treg cell depletion therapy (eg, anti-CD25 antibody).

[0011] Another aspect of the present invention provides a cancer vaccine for treating cancer, wherein the cancer vaccine is used in combination with a Fas axis antagonist (eg, anti-FasL antibody) and a Treg cell depletion therapy (eg, anti-CD25 antibody).

[0012] Another aspect of the present invention provides a method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of each of a Treg cell depletion therapy and a Fas axis antagonist.

[0013] Another aspect of the invention provides a method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of each of an anti-CD25 antibody and an anti-FasL antibody.

[0014] Another aspect of the invention provides a Fas axis antagonist (eg, anti-FasL antibody) for use in treating or preventing cancer recurrence in a subject, wherein the subject has received Treg cell depletion therapy for treating cancer, and wherein the Fas axis antagonist is administered to the subject after the Treg cell depletion therapy.

[0015] Another aspect of the present invention provides Treg cell depletion therapy for treating or preventing cancer recurrence in a subject, wherein the Treg cell depletion therapy is used in combination with at least one administration of a Fas axis antagonist (e.g., an anti-FasL antibody), wherein the Fas axis antagonist is administered to the subject after the Treg cell depletion therapy.

[0016] Another aspect of the invention provides a method for treating or preventing cancer recurrence in a subject, wherein the subject has received Treg cell depletion therapy for treating cancer, wherein the method comprises administering to the subject at least one dose of a Fas axis antagonist (e.g., an anti-FasL antibody) after the Treg cell depletion therapy.

[0017] Another aspect of the present invention provides a method for treating or preventing cancer recurrence in a subject, comprising administering to the subject:

[0018] a) priming administration of Treg cell depletion therapy; and

[0019] b) booster administration of Treg cell depletion therapy and administration of Fas axis antagonists;

[0020] Here, the booster administration of Treg cell depletion therapy was administered before the Fas axis antagonist.

[0021] Another aspect of the present invention provides a priming administration of Treg cell depletion therapy for treating or preventing cancer recurrence in a subject, wherein the subject is also administered a booster administration of Treg cell depletion therapy and an administration of a Fas axis antagonist, wherein the booster administration of Treg cell depletion therapy is administered before the Fas axis antagonist.

[0022] Another aspect of the present invention provides the following combination for treating or preventing cancer recurrence in a subject: a) priming administration of Treg cell depletion therapy; b) boosting administration of Treg cell depletion therapy; and c) administration of a Fas axis antagonist, wherein the priming administration of Treg cell depletion therapy and the boosting administration of Treg cell depletion therapy are administered before the Fas axis antagonist.

[0023] Another aspect of the present invention provides a method for treating or preventing cancer recurrence in a subject, comprising administering to the subject:

[0024] a) priming administration of an anti-CD25 antibody; and

[0025] b) booster administration of anti-CD25 antibody and administration of anti-FasL antibody,

[0026] The booster dose of anti-CD25 antibody was administered before the anti-FasL antibody.

[0027] Another aspect of the invention provides a priming administration of an anti-CD25 antibody for treating or preventing cancer recurrence in a subject, wherein the subject is further administered a boosting administration of the anti-CD25 antibody and an administration of an anti-FasL antibody, wherein the boosting administration of the anti-CD25 antibody is administered prior to the anti-FasL antibody.

[0028] The present invention also provides embodiments of any of the above aspects, wherein a cancer vaccine is further administered to the subject, and / or the subject also receives cancer vaccine therapy.

[0029] The invention also provides for use of a component or combination of components in any of the disclosed methods of treatment.

[0030] Other aspects and embodiments of the invention are described in more detail below. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1: Study design of the mouse in vivo model. On day 0, 50,000 B16 / BL6 melanoma cells were injected subcutaneously (sc) into the right flank of C57BL / 6 mice. The mice were divided into 4 groups ( Figure 1 AD), and 200 μg of anti-CD25 NIB Antibody, 1×10 6 irradiated (150 Gy) GVAX, isotype control and / or 200 μg anti-FasL (MFL3) antibody.

[0032] Figure 2 : In vivo mouse model showing tumor growth after initial combination therapy including anti-CD25 antibody and cancer vaccine followed by further treatment with: (A) isotype control, (B) anti-FasL antibody, (C) weekly anti-CD25 antibody, and (D) anti-FasL antibody and anti-CD25 antibody.

[0033] Figure 3 : Survival of animals in a mouse cancer model at the indicated days following initial combination therapy including anti-CD25 antibody and cancer vaccine followed by treatment with isotype control, anti-FasL antibody, weekly anti-CD25 antibody, or a combination of anti-FasL antibody and anti-CD25 antibody. DETAILED DESCRIPTION

[0034] The present invention provides a combination of Treg cell depletion therapy and Fas axis binding antagonist for treating cancer in a subject. Specifically, the present invention provides Treg cell depletion therapy (e.g., anti-CD25 antibody) as a first component, and Fas axis binding antagonist (e.g., anti-FasL antibody) as a second (and optional subsequent) component for treating cancer in a subject. The present invention also provides a method for treating cancer in a subject, comprising administering Treg cell depletion therapy such as anti-CD25 antibody, and administering Fas axis binding antagonist such as anti-FasL antibody.

[0035] Reference herein to "combination" or "in conjunction" refers to separate, simultaneous or sequential administration, unless the context dictates otherwise.

[0036] The present inventors have found that the combined administration of anti-CD25 antibodies and Fas axis binding antagonists helps prevent tumor recurrence and improve the therapeutic effect of anti-CD25 antibody treatment. It is known that Treg helps to form an immunosuppressive tumor microenvironment (TME). In humans, the tumor infiltration rate of Treg cells is high, and more importantly, the ratio of effector T cells (Teff) to Treg cells is low, which is associated with poor prognosis in a variety of human cancers (Shang et al., 2015, Sci Rep. 5: 15179). In contrast, high Teff / Treg cell ratios are associated with good responses to immunotherapy in humans and mice (Hodi et al., 2008, Proc. Natl. Acad. Sci. USA, 105, 3005-3010; Quezada et al., 2006, J Clin Invest. 116 (7): 1935-45). However, during anti-CD25 antibody treatment, the inventors have found that in partially responsive tumors, the tumor microenvironment (TME) changes over time. Characterization of the TME in partially responding tumors revealed changes including loss of activated effector T cells, gain of resting T cells, increase of regulatory T cells (Tregs), and increase of M2-like suppressive myeloid cells. Such changes in the TME, especially over time, where active Teff cells may be lost and Treg cells may be increased, may contribute to relapse of previously responding tumors.

[0037] The inventors found that blocking the Fas / FasL axis with an inhibitor of the FasL / Fas signaling system (i.e., a Fas axis antagonist), such as an anti-FasL antibody or an anti-Fas antibody, can inhibit Fas-mediated cell death of activated Teff cells. Compared with other T cells, the expression of Fas in activated Teff cells is higher; and in stable tumors before relapse, the %Fas+ cells in activated Teff cells show an increasing trend, which indicates that activated Teff may be more susceptible to Fas-mediated cell death.

[0038] Specifically, the inventors found that the combined administration of inhibitors of the FasL / Fas signaling system (i.e., Fas axis antagonists), such as anti-FasL antibodies or anti-Fas antibodies, and Treg cell depletion therapy (e.g., by administering anti-CD25 antibodies), optionally further combined with a cancer vaccine (e.g., GVAX), can maintain an immunogenic tumor microenvironment (TME), in particular, maintain a high Teff / Treg cell ratio, thereby enabling better therapeutic outcomes.

[0039] The treatment regimen of the present invention produces an enhanced therapeutic effect compared to the administration of anti-CD25 alone, or the combination of anti-CD25 and cancer vaccine, or the administration of Fas axis antagonists (eg, anti-FasL antibodies) alone.

[0040] Therefore, the first aspect of the present invention provides a combination comprising Treg cell depletion therapy and a Fas axis antagonist for treating cancer. Treg cell depletion therapy and Fas axis antagonist are administered separately, simultaneously or sequentially. In one embodiment, the combination comprises: a) a first component comprising Treg cell depletion therapy; and b) a second component comprising a Fas axis antagonist, the first component and the second component being used separately, simultaneously or sequentially for cancer treatment.

[0041] Treg cell depletion therapy can be administered in combination with one or more other therapeutic agents. Preferably, the other therapeutic agent is a cancer vaccine. Therefore, in some embodiments, Treg cell depletion therapy is administered in combination with a cancer vaccine, wherein the cancer vaccine is administered separately, simultaneously or sequentially from the Treg cell depletion therapy.

[0042] Therefore, in one embodiment of the present invention, a combination for treating cancer is provided, comprising: a) a first component comprising Treg cell depletion therapy, b) a second component comprising a Fas axis antagonist, and c) a third component comprising a cancer vaccine. Treg cell depletion therapy, Fas axis antagonist and cancer vaccine are preferably administered separately. Preferably, Treg cell depletion therapy is administered to the subject, then a cancer vaccine is administered to the subject, and then a Fas axis antagonist is administered to the subject.

[0043] Preferably, the treatment regimen may include multiple administrations of Treg cell depletion therapy, Fas axis antagonists, and / or cancer vaccines.

[0044] In a preferred embodiment of the present invention, Treg cell depletion therapy comprises administering anti-CD25 antibodies, preferably in combination with cancer vaccines. The combined administration of anti-CD25 antibodies and cancer vaccines enhances the therapeutic effect of Treg cell depletion therapy.

[0045] In a preferred embodiment of the present invention, the Fas axis antagonist is an anti-FasL antibody. Therefore, in one embodiment of the present invention, a combination is provided, which comprises: a) a first component comprising an anti-CD25 antibody, b) a second component comprising an anti-FasL antibody, and c) a third component comprising a cancer vaccine, wherein the first component, the second component and the third component are used simultaneously, separately or sequentially for treating cancer.

[0046] Preferably, the Fas axis antagonist (e.g., anti-FasL antibody) is administered after the administration of the anti-CD25 antibody and the cancer vaccine. By "administered afterwards," it is meant that the Fas axis antagonist (e.g., anti-FasL antibody) is preferably administered long enough after the administration of the anti-CD25 antibody (and optionally after the administration of the cancer vaccine) to allow these components to achieve their desired effects. For example, the Fas axis antagonist (e.g., anti-FasL antibody) is administered after the depletion of Treg cells in the subject is achieved by the administration of the anti-CD25 antibody (and optionally the administration of the cancer vaccine).

[0047] In a preferred embodiment, the treatment regimen comprises administering to the subject an anti-CD25 antibody, followed by a cancer vaccine, and then a Fas axis antagonist (eg, an anti-FasL antibody).

[0048] The treatment regimen may include multiple administrations of anti-CD25 antibodies, cancer vaccines, and / or Fas axis antagonists (e.g., anti-FasL antibodies). In one embodiment, the treatment regimen includes multiple administrations of anti-FasL antibodies. In one embodiment, the anti-FasL antibodies are administered in conjunction with further administrations of anti-CD25 antibodies, wherein the further administrations of anti-CD25 antibodies are administered before the anti-FasL antibodies. In other words, the treatment regimen includes administering a first administration of anti-FasL antibodies after at least two administrations of anti-CD25 antibodies. Multiple administrations of anti-CD25 antibodies may be administered to maintain Treg depletion in the subject.

[0049] In one embodiment, the second dose of anti-CD25 antibody is administered at least 7 days after the first dose of anti-CD25 antibody, preferably at least 10 days after the first dose of anti-CD25 antibody, and more preferably 14 to 35 days after the first dose of anti-CD25 antibody.

[0050] In one embodiment, each administration of the anti-FasL antibody is administered within 20 days of the second administration and each subsequent administration of the anti-CD25 antibody. For example, it is preferred to administer the anti-FasL antibody after achieving Treg cell depletion in the subject by administering the anti-CD25 antibody. Preferably, each administration of the anti-FasL antibody is administered at least 1 day, preferably at least 3 days, and more preferably at least 7 days after the second administration and each subsequent administration of the anti-CD25 antibody.

[0051] The administration of anti-FasL antibody is repeated multiple times, i.e., periodically, after the second administration of anti-CD25 antibody. Each combined administration of anti-CD25 antibody and anti-FasL antibody can be referred to as a treatment cycle. In one embodiment, each treatment cycle of the anti-CD25 antibody / anti-FasL antibody combination is repeated multiple times, preferably with at least seven days between the start of each cycle, i.e., each treatment cycle including the administration of anti-CD25 antibody and anti-FasL antibody is performed over a period of at least 7 days.

[0052] Preferably, each treatment cycle is within the range of 7 to 48 days, wherein the start of each treatment cycle (i.e., day 1 of the cycle) is calculated from the administration of the anti-CD25 antibody. The treatment cycle may include a rest period, i.e., the treatment cycle may include a time period in which the antibody is not administered or the cancer vaccine is not administered optionally. In some embodiments, each subsequent administration of the anti-CD25 antibody is administered once a week (Q1W), once every two weeks (Q2W), once every three weeks (Q3W), or once every six weeks (Q6W), wherein the administration of the anti-FasL antibody is administered between each administration of the anti-CD25 antibody. Each subsequent administration of the anti-CD25 antibody is administered at a certain frequency to maintain the Treg cell consumption of the subject.

[0053] For example, in one embodiment, anti-FasL antibody is administered 7 days after each further administration of anti-CD25 antibody, wherein the administration of anti-FasL antibody and anti-CD25 antibody is repeated multiple times, and the interval between each administration of anti-CD25 antibody is at least 14 days. For example, anti-CD25 antibody is administered on day 1 of each treatment cycle, and anti-FasL antibody is administered on day 8 of the treatment cycle, wherein each treatment cycle is at least 14 days, and wherein if a cancer vaccine is administered, the vaccine can be administered on any one or more days of days 2-7 of each treatment cycle.

[0054] Preferably, the Fas axis antagonist (eg, anti-FasL antibody) is administered when the subject has depleted Treg levels due to treatment with an anti-CD25 antibody (and optionally a cancer vaccine).

[0055] In embodiments where the treatment regimen includes administration of a cancer vaccine, the first administration of the cancer vaccine is preferably administered prior to the first administration of a Fas axis antagonist (eg, anti-FasL antibody) and prior to the second administration of an anti-CD25 antibody.

[0056] The treatment regimen may also include administering multiple doses of the cancer vaccine. Preferably, one or more doses of the cancer vaccine are administered after the first dose of the anti-CD25 antibody has been administered. In a further embodiment, the cancer vaccine may be administered substantially simultaneously with the anti-CD25 antibody. The treatment regimen may include:

[0057] - Anti-CD25 antibody is administered first;

[0058] - one or more subsequent administrations of a cancer vaccine;

[0059] - subsequently administering one or more alternating administrations of the anti-CD25 antibody and the Fas axis antagonist, wherein each further administration of the anti-CD25 antibody is administered prior to the administration of the Fas axis antagonist.

[0060] Thus, in one embodiment, the treatment regimen comprises, in sequence:

[0061] a) administering an anti-CD25 antibody;

[0062] b) administering a cancer vaccine, preferably wherein administering the cancer vaccine comprises administering multiple doses of the cancer vaccine, preferably 3 doses of the cancer vaccine;

[0063] c) administering an anti-CD25 antibody; and

[0064] d) administration of a Fas axis antagonist (e.g., anti-FasL antibody),

[0065] Wherein the treatment regimen comprises repeating steps c) and d) in a cyclic manner. Preferably, each treatment cycle comprising steps c) to d) is performed for a period of at least 7 days. For example, each administration of the anti-CD25 antibody and the Fas axis antagonist administered in steps c) and d) is administered Q1W, Q2W, Q3W or Q6W. Preferably, each subsequent administration of the anti-CD25 antibody is administered at a certain frequency to maintain the Treg cell depletion of the subject. Preferably, the Fas axis antagonist is administered after the Treg cell depletion of the subject is achieved by administering the anti-CD25 antibody.

[0066] In some embodiments, further administrations of the cancer vaccine may also be combined with second and subsequent administrations of the anti-CD25 antibody. In other words, the treatment regimen may include:

[0067] - Anti-CD25 antibody is administered first;

[0068] - one or more subsequent administrations of a cancer vaccine;

[0069] - subsequently administering one or more administrations of an anti-CD25 antibody, a cancer vaccine, and a Fas axis antagonist, wherein each further administration of the anti-CD25 antibody is administered before an administration of the Fas axis antagonist, and wherein each further administration of the cancer vaccine is administered between each further administration of the anti-CD25 antibody and the Fas axis antagonist.

[0070] Thus, in one embodiment, the treatment regimen comprises, in sequence:

[0071] a) administering an anti-CD25 antibody;

[0072] b) administering a cancer vaccine, preferably wherein administering the cancer vaccine comprises administering multiple administrations of the cancer vaccine, preferably 3 administrations of the cancer vaccine;

[0073] c) administering anti-CD25 antibodies;

[0074] d) administering cancer vaccines; and

[0075] e) administering a Fas axis antagonist (e.g., anti-FasL antibody),

[0076] Wherein the treatment regimen comprises repeating steps c) to e) in a cyclic manner. Preferably, each treatment cycle comprising steps c) to e) is performed for a period of at least 7 days. For example, each administration of the components administered in steps c) to e) is administered Q1W, Q2W, Q3W or Q6W. Preferably, each subsequent administration of the anti-CD25 antibody is administered at a certain frequency to maintain the Treg cell depletion of the subject. Preferably, the Fas axis antagonist is administered after the Treg cell depletion of the subject is achieved by administering the anti-CD25 antibody.

[0077] In some embodiments of the invention, the initial administration of Treg cell depletion therapy (e.g., anti-CD25 antibody), and the initial one or more administrations of an optional cancer vaccine can be considered as priming therapy. The second and subsequent administrations of Treg cell depletion therapy, such as subsequent anti-CD25 antibody administrations, and further administrations of optional cancer vaccines, can be considered as boosting therapy.

[0078] "Priming therapy" according to the present invention includes administering Treg cell depletion therapy (e.g., anti-CD25 antibodies) and optionally a cancer vaccine administered after the Treg cell depletion therapy. In some embodiments, priming therapy may include administering multiple doses of a cancer vaccine after administering the Treg cell depletion therapy.

[0079] A "boost cycle," "boost therapy," or "boost treatment" or similar terms according to the present invention includes the administration of Treg cell depletion therapy (e.g., anti-CD25 antibodies) and a Fas axis antagonist (e.g., anti-FasL antibodies), and optionally a cancer vaccine. Each boost cycle or therapy includes the administration of Treg cell depletion therapy, followed by one or more administrations of a cancer vaccine (if used), and then the administration of a Fas axis antagonist. Preferably, the Fas axis antagonist is administered after the subject's Treg cell depletion is achieved by administering Treg cell depletion therapy (and an optional cancer vaccine). Preferably, the present invention includes multiple rounds of boost therapy, for example, each boost cycle is repeated multiple times, i.e., performed two, three, four or more times.

[0080] Therefore, in another aspect of the present invention, a priming administration of Treg cell depletion therapy for treating cancer in a subject and an optional priming administration of a cancer vaccine are provided, wherein a Fas axis antagonist (e.g., an anti-FasL antibody) is further administered to the subject and a booster administration of Treg cell depletion therapy, wherein the booster administration of Treg cell depletion therapy is administered before the Fas axis antagonist. In some embodiments, the booster administration of Treg cell depletion therapy can be administered in combination with a further booster administration of a cancer vaccine.

[0081] By "administered prior to" is meant that the Treg cell depletion therapy (eg, anti-CD25 antibody) is preferably administered long enough before the administration of the Fas axis antagonist to allow the Treg cell depletion therapy to achieve its intended effect (eg, deplete the subject's Treg cells).

[0082] In one embodiment, a priming administration of an anti-CD25 antibody and optionally a priming administration of a cancer vaccine for treating cancer in a subject is provided, wherein the subject is further administered an administration of an anti-FasL antibody and a boosting administration of an anti-CD25 antibody, wherein the boosting administration of the anti-CD25 antibody is administered before the anti-FasL antibody. In some embodiments, the boosting administration of the cancer vaccine may be administered after the boosting administration of the anti-CD25 antibody, followed by the administration of the anti-FasL antibody.

[0083] In one embodiment, administration of an anti-FasL antibody for treating cancer in a subject is provided, wherein the subject is first administered a priming administration of an anti-CD25 antibody, optionally a priming administration of a cancer vaccine, and a boosting administration of an anti-CD25 antibody.

[0084] Another embodiment of the present invention provides a method of treating cancer in a subject, comprising administering to the subject:

[0085] a) priming administration of anti-CD25 antibodies and priming administration of cancer vaccines; and

[0086] b) administration of anti-FasL antibody and booster administration of anti-CD25 antibody,

[0087] The booster dose of anti-CD25 antibody was administered before the anti-FasL antibody.

[0088] Preferably, after the priming administration of anti-CD25 antibody, anti-FasL antibody and booster administration of anti-CD25 antibody are periodically administered, i.e., step b) is repeated twice, three times, four times or more. Preferably, each treatment cycle is at least 7 to 48 days, wherein the beginning of each cycle (i.e., the first day of each cycle) is calculated from the administration of booster administration of anti-CD25 antibody. For example, each booster administration of anti-CD25 antibody is administered Q1W, Q2W, Q3W or Q6W, wherein the administration of anti-FasL antibody is administered between each administration of anti-CD25 antibody. The booster administration of anti-CD25 antibody is administered at a certain frequency to maintain the Treg cell consumption of the subject. Preferably, anti-FasL antibody is administered after the Treg cell consumption of the subject is achieved by administering anti-CD25 antibody.

[0089] Preferably, the anti-FasL antibody is administered within 20 days after each booster administration of the anti-CD25 antibody. More preferably, each administration of the anti-FasL antibody is administered at least 1 day, preferably at least 3 days, more preferably at least 7 days after each booster administration of the anti-CD25 antibody.

[0090] For example, in one embodiment, boosting doses of anti-CD25 antibody are administered on day 1 of each boosting cycle, and anti-FasL antibody is administered on day 7 or later of each cycle, wherein each cycle is a cycle of at least 14 days.

[0091] In one embodiment, the initial priming therapy of anti-CD25 antibody and cancer vaccine may include multiple administrations of the cancer vaccine.

[0092] Preferably, multiple doses of the cancer vaccine are administered after a priming dose of the anti-CD25 antibody and prior to administration of subsequent doses of the anti-CD25 antibody. Preferably, the first dose of the cancer vaccine is administered at least 1 day after administration of the anti-CD25 antibody.

[0093] In one embodiment, the first boost cycle begins at least 7 days after the priming administration of the anti-CD25 antibody, preferably at least 10 days after the priming administration of the anti-CD25 antibody, and more preferably 14 to 35 days after the priming administration of the anti-CD25 antibody. Each boost cycle is preferably at least 7 days, and more preferably each boost immunization cycle is 7 to 48 days. Preferably, the anti-CD25 antibody and the anti-FasL antibody are each administered once per cycle. In some embodiments, the boost administration of the cancer vaccine can be combined with the boost administration of the anti-CD25 antibody in each anti-CD25 antibody / anti-FasL antibody cycle. Preferably, the boost administration of the cancer vaccine is administered between each administration of the anti-CD25 antibody and the anti-FasL antibody in each boost cycle.

[0094] Another aspect of the invention relates to treating or preventing cancer recurrence in a subject. One embodiment of the invention provides a method of treating or preventing cancer recurrence in a subject, wherein the subject has received Treg cell depletion therapy for treating cancer, wherein the method comprises administering to the subject at least one dose of a Fas axis antagonist, such as an anti-FasL antibody, after the Treg cell depletion therapy.

[0095] In one embodiment, the present invention provides a method for treating or preventing cancer recurrence in a subject, comprising:

[0096] a) administering a priming dose of Treg cell depletion therapy;

[0097] b) administering one or more priming doses of a cancer vaccine;

[0098] c) administering a booster dose of Treg cell depletion therapy;

[0099] d) optionally administering booster doses of the cancer vaccine; and

[0100] e) administration of a Fas axis antagonist,

[0101] Wherein the method comprises repeating steps c) to e) in a cyclic manner. Preferably, each treatment cycle comprising steps c) to e) is performed for a period of at least 7 days. For example, each administration of the components administered in steps c) to e) is administered Q1W, Q2W, Q3W or Q6W. Preferably, each subsequent administration of the anti-CD25 antibody is administered at a certain frequency to maintain the Treg cell consumption of the subject. Preferably, the Fas axis antagonist is administered after the Treg cell consumption of the subject is achieved by administering the anti-CD25 antibody (and an optional cancer vaccine).

[0102] Another embodiment of the present invention provides a Fas axis antagonist, such as an anti-FasL antibody, for treating or preventing cancer recurrence in a subject, wherein the subject has received Treg cell depletion therapy for treating cancer, and wherein the Fas axis antagonist is administered to the subject after the Treg cell depletion therapy.

[0103] Another embodiment of the present invention provides a Treg cell depletion therapy for treating or preventing cancer recurrence in a subject, wherein the Treg cell depletion therapy is used in combination with at least one administration of a Fas axis antagonist (e.g., an anti-FasL antibody), wherein the Fas axis antagonist is administered to the subject after the Treg cell depletion therapy.

[0104] Another embodiment of the present invention provides a combination of a) a priming administration of Treg cell depletion therapy; b) a boosting administration of Treg cell depletion therapy, and c) administration of a Fas axis antagonist for treating or preventing cancer recurrence in a subject, wherein the priming administration of Treg cell depletion therapy and the first boosting administration of Treg cell depletion therapy are administered before the Fas axis antagonist.

[0105] Another embodiment of the present invention provides a combination of a) a priming administration of Treg cell depletion therapy; b) a priming administration of a cancer vaccine, c) a boosting administration of Treg cell depletion therapy, and d) administration of a Fas axis antagonist for treating or preventing cancer recurrence in a subject, wherein the priming administration of Treg cell depletion therapy, the priming administration of the cancer vaccine, and the boosting administration of Treg cell depletion therapy are administered before the Fas axis antagonist, and wherein the priming administration of the cancer vaccine is administered between the priming administration of Treg cell depletion therapy and the first boosting administration of Treg cell depletion therapy.

[0106] In some embodiments, the treatment comprises repeated administration of booster doses of Treg cell depletion therapy and a Fas axis antagonist, wherein each booster dose of Treg cell depletion therapy is administered prior to each dose of the Fas axis antagonist. The repeated administration of each booster dose of Treg cell depletion therapy and a dose of the Fas axis antagonist is performed periodically.

[0107] Preferably, the combination further comprises e) booster administration of a cancer vaccine, wherein each booster administration of the cancer vaccine is administered between each booster administration of the Treg cell depletion therapy and each administration of the Fas axis antagonist. The repeated administration of each booster administration of the Treg cell depletion therapy, each booster administration of the cancer vaccine, and each booster administration of the Fas axis antagonist is performed periodically.

[0108] Preferably, each treatment cycle is carried out for a period of at least 7 days. Preferably, the range of each cycle is 7 to 48 days, wherein the beginning of each cycle (i.e., the first day of each cycle) is calculated from the boost administration of anti-CD25 antibodies. The boost administration of Treg cell depletion therapy (e.g., anti-CD25 antibodies) is administered at a certain frequency to maintain the Treg cell consumption of the subject. Preferably, a Fas axis antagonist (e.g., anti-FasL antibody) is administered after the Treg cell consumption of the subject is achieved by administering Treg cell depletion therapy.

[0109] Treating or preventing the recurrence of cancer means avoiding the recurrence, return, or reappearance of cancer after an initial response or partial response to previous cancer treatment. For example, in the treatment of solid tumors, the recurrence of cancer may involve an increase in the size of the tumor.

[0110] Treg cell depletion therapy preferably includes the administration of anti-CD25 antibodies. In some embodiments, anti-CD25 antibodies are administered in combination with another therapeutic agent (e.g., a cancer vaccine). The combination of anti-CD25 antibodies and cancer vaccines can be administered as described in the first aspect of the present invention.

[0111] The Fas axis antagonist (e.g., anti-FasL antibody) is preferably administered in combination with further administration of anti-CD25 antibody, wherein the anti-FasL antibody is administered after the further administration of anti-CD25 antibody. The combination of anti-FasL antibody and anti-CD25 antibody and the optional cancer vaccine may be administered periodically as described in the first aspect of the invention.

[0112] Another aspect of the present invention is a method of treating or preventing cancer recurrence in a subject, comprising administering to the subject a therapeutically effective amount of Treg cell depletion therapy and a therapeutically effective amount of a Fas axis antagonist.

[0113] Another aspect of the present invention is the use of Treg cell depletion therapy and a Fas axis antagonist in the manufacture of a medicament for treating cancer.

[0114] Another aspect of the present invention provides an anti-CD25 antibody for use in treating cancer, wherein the anti-CD25 antibody is used in combination with an anti-FasL antibody.

[0115] Another aspect of the present invention provides use of an anti-CD25 antibody in the manufacture of a medicament for treating cancer, wherein the anti-CD25 antibody is used in combination with an anti-FasL antibody.

[0116] Another aspect of the present invention provides an anti-FasL antibody for use in treating cancer, wherein the anti-FasL antibody is used in combination with an anti-CD25 antibody.

[0117] Another aspect of the present invention provides an anti-FasL antibody for use in the manufacture of a medicament for treating cancer, wherein the anti-FasL antibody is used in combination with an anti-CD25 antibody.

[0118] Another aspect of the present invention provides a cancer vaccine for treating cancer, wherein the cancer vaccine is used in combination with an anti-FasL antibody and an anti-CD25 antibody.

[0119] Another aspect of the present invention provides use of a cancer vaccine in the manufacture of a medicament for treating cancer, wherein the cancer vaccine is used in combination with an anti-FasL antibody and an anti-CD25 antibody.

[0120] Although some aspects and embodiments of the present invention further describe that the Fas axis antagonist is an anti-FasL antibody and the Treg cell depletion therapy includes the administration of an anti-CD25 antibody, other Fas axis antagonists and Treg cell depletion therapies can also be used in the present invention. The present invention relates to the treatment of cancer. In one embodiment, the cancer is a CD25 positive cancer. The cancer can be a blood cancer or a solid cancer.

[0121] In some embodiments, the cancer is selected from acute myeloid leukemia, diffuse large cell B-cell lymphoma, melanoma, non-small cell lung cancer, renal cancer, ovarian cancer, bladder cancer, sarcoma, colorectal cancer, or more generally, any human cancer, as long as the B16 cell line can represent a useful preclinical model for validating compounds for their therapeutic management.

[0122] In some embodiments, cancer relates to solid tumors (e.g., solid tumor cancers), and treatment is used to treat cancer or prevent solid tumor recurrence. "Solid tumor" as used herein is an abnormal growth or mass of tissue, generally not comprising a cyst or liquid area, particularly a tumor and / or metastasis (wherever located) other than leukemia or non-solid lymphoma. Solid tumors may be benign or malignant. Different types of solid tumors are named according to the cell type and / or tissue or organ in which they are formed. Examples of solid tumors include sarcomas (including cancers of transformed cells of mesenchymal origin derived from tissues such as cancellous bone, cartilage, fat, muscle, blood vessels, hematopoiesis or fibrous connective tissue), cancers (including tumors derived from epithelial cells), mesotheliomas, neuroblastomas, retinoblastomas, etc.

[0123] As used herein, "treating" or "managing" cancer is defined as achieving at least one positive therapeutic effect, such as reducing the number of cancer cells, reducing tumor size, reducing the rate of cancer cell infiltration into peripheral organs, or reducing the rate of tumor metastasis or tumor growth.

[0124] The positive treatment effect of cancer can be measured in a variety of ways (e.g., Weber (2009) J Nucl Med 50, 1S-10S). For example, in terms of tumor growth inhibition, according to the criteria of the National Cancer Institute (NCI), a T / C% ratio of 42% is the lowest level of anti-tumor activity. T / C <10% is considered a high level of anti-tumor activity, where T / C (%) = median volume of treated tumors / median volume of control tumors × 100. In some embodiments, the treatment achieved by a therapeutically effective amount is any one of progression-free survival (PFS), disease-free survival (DFS), or overall survival (OS). PFS, also known as "time to tumor progression," indicates the length of time that cancer does not grow during and after treatment, including the time a patient experiences a complete response or partial response, and the time a patient experiences stable disease. DFS refers to the length of time a patient survives disease-free during and after treatment. OS refers to the extension of life expectancy compared to an original or untreated individual or patient.

[0125] As used herein, "prevention," "prevention" (or prophylaxis) refers to delaying or preventing the onset of cancer symptoms. Prevention may be absolute (ie, the disease will not occur) or may be effective only in certain individuals or for a limited time.

[0126] The present invention relates to the use of Fas axis binding antagonists. The term "Fas axis binding antagonist" as used herein is a molecule that inhibits the interaction of Fas binding partners with FasL, thereby blocking the Fas / FasL signaling pathway (also known as the CD95 / CD95L pathway) and inhibiting Fas-mediated cell death. Specifically, the FAS axis binding antagonist used in the present invention blocks FasL / Fas-induced apoptosis. Methods for targeting FasL / Fas signaling are discussed in Risso V et al (2022) Cell Death and Disease vol 13A248.

[0127] FasL, also known as Fas ligand, CD95L or CD178, is a type II membrane-bound protein belonging to the tumor necrosis factor (TNF) family. FasL is a protein that binds to its receptor Fas (also known as FasR, APO-1 or CD95) and induces apoptosis. FasL is mainly expressed on activated T cells and natural killer (NK) cells. The Fas-FasL signaling pathway regulates immune responses by inducing apoptosis.

[0128] Fas axis binding antagonists include Fas inhibitors, such as anti-Fas antibodies or antigen binding fragments thereof, and FasL inhibitors, such as anti-FasL antibodies or antigen binding fragments thereof. Non-antibody inhibitors of FAS axis binding antagonists are also contemplated, such as the FasL inhibitor asunercept (APG101), which is a glycosylated fusion protein comprising the extracellular domain of human CD95 linked to the Fc domain of human IgG1.

[0129] In one embodiment of the present invention, the Fas axis binding antagonist is an anti-FasL antibody. As used herein, "anti-FasL antibody" refers to an antibody or an antibody binding fragment thereof that is capable of binding to FasL. The anti-FasL antibody is a "neutralizing" or "antagonistic" antibody, which means that the binding of the antibody to FasL results in the inhibition of biological activity induced by the FasL polypeptide. The antibody can specifically bind to the binding site of FasL that binds to Fas, thereby preventing FasL from binding to Fas. Preferably, the ability of the antibody to neutralize or antagonize FasL activity can be assessed by its ability to inhibit Fas-FasL-mediated apoptosis. Anti-FasL antibodies can inhibit apoptosis of Fas antigen-expressing cells induced by Fas ligand. The activity of anti-FasL antibodies can be assessed by assays and methods known in the art.

[0130] Anti-FasL antibodies are known in the art. Examples of anti-FasL antibodies are disclosed in, for example, WO2003 / 079750, WO1996 / 029350, EP0842948 and EP0872488. The contents thereof are incorporated herein by reference.

[0131] A Fas axis binding antagonist is administered to a subject who has received Treg cell depletion therapy.

[0132] As used herein, "Treg cell depletion therapy" or "Treg depletion therapy" refers to a treatment regimen that results in a reduction in the Treg level of a subject compared to the Treg level of the subject before treatment. Compounds that consume Treg cells are known in the art. The consumption of Tregs can be measured by techniques known in the art, such as WO2018 / 167104 and Simpson et al (2013) J Exp Med 210, 1695-710. The contents are incorporated herein by reference.

[0133] "Regulatory T cells" ("Treg", "Treg cells" or "Tregs") used herein refer to CD4+T lymphocyte lineages that specifically control autoimmunity, allergies and infections. Typically, they regulate the activity of T cell populations, but they can also affect certain innate immune system cell types. Tregs are typically identified by the expression of biomarkers CD4, CD25, and Foxp3. Naturally occurring Treg cells typically account for about 5% to 10% of peripheral CD4+T lymphocytes. However, in the tumor microenvironment (i.e., tumor-infiltrating Treg cells), they can account for 20% to 30% of the total CD4+T lymphocyte population.

[0134] In a preferred embodiment of the present invention, Treg cell depletion therapy comprises administering to a subject an anti-CD25 antibody alone or in combination with other therapeutic agents. Preferably, the other therapeutic agent is a cancer vaccine.

[0135] CD25 is the α chain of the IL-2 receptor, present in activated T cells, regulatory T cells, activated B cells, some NK T cells, some thymocytes, myeloid precursor cells and oligodendrocytes. CD25 associates with CD122 and CD132 to form a heterotrimeric complex that is a high-affinity receptor for IL-2. The consensus sequence of human CD25 is shown below and is identified as SEQ ID NO: 1 (Uniprot accession number P01589; the extracellular domain of mature human CD25, corresponding to underlined amino acids 22-240).

[0136]

[0137] As used herein, "anti-CD25 antibody" or "antibody that binds to CD25" refers to an antibody that is capable of binding to the CD25 subunit of the IL-2 receptor. This subunit is also known as the α subunit of the IL-2 receptor.

[0138] The anti-CD25 antibody is an antibody that can specifically bind to the CD25 subunit (antigen) of the IL-2 receptor.

[0139] "Specific binding", "specifically binds" and "specific binding" are understood to mean that the dissociation constant (Kd) of the antibody for the target antigen is less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, 10 -12 M or 10 -13 In a preferred embodiment, the dissociation constant is less than 10 -8 M, for example, in 10 -9 M, 10 -10M, 10 -11 M, 10 -12 M or 10 -13 Within the range of M.

[0140] Anti-CD25 antibodies suitable for use in the present invention are antibodies that are capable of depleting or reducing Treg cells.

[0141] As used herein, reference to "depletion" or "depletion" (with respect to depletion of regulatory T cells by an anti-CD25 antibody agent) refers to a decrease in the number, ratio or percentage of Tregs compared to when the antibody is not administered. In specific embodiments of the invention described herein, greater than about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 99% of regulatory T cells are depleted.

[0142] Anti-CD25 antibodies capable of depleting Treg cells and suitable for use in the present invention include, for example, those described in WO2017 / 174331, WO2018 / 167104, WO2019 / 008386, WO2019 / 175215, WO2019 / 175216, WO2019 / 175217, WO2019 / 175220, WO2019 / 17522, WO2019 / 175223, WO2019 / 175224, WO2019 / 175226, the contents of which are incorporated herein by reference.

[0143] In a preferred embodiment of the invention, the anti-CD25 antibody binds to FcγR with high affinity, preferably to an activating receptor with high affinity. Preferably, the antibody binds to FcγRI and / or FcγRIIa and / or FcγRIIIa with high affinity. In a specific embodiment, the antibody binds to FcγR with an affinity of less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 The dissociation constant of M binds to at least one activated Fcγ receptor.

[0144] In some embodiments, the antibody is an IgG1 antibody, preferably a human IgG1 antibody, which is capable of binding to at least one Fc activating receptor. For example, the antibody can bind to one or more receptors selected from FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa, and FcγRIIIb. In some embodiments, the antibody is capable of binding to FcγRIIIa. In some embodiments, the antibody is capable of binding to FcγRIIIa and FcγRIIa and optionally FcγRI. In some embodiments, the antibody is capable of binding to these receptors with high affinity, for example, with a dissociation constant of less than about 10 -7 M, 10-8 M, 10 -9 M or 10 -10 M.

[0145] In some embodiments, the antibody binds to the inhibitory receptor FcγRIIb with low affinity. In some embodiments, the antibody binds to the inhibitory receptor FcγRIIb with an affinity greater than about 10 -7 M, above about 10 -6 M or above about 10 -5 The dissociation constant of M binds to FcγRIIb.

[0146] In some embodiments, the anti-CD25 antibody can be afucosylated. The Fc region of the antibody can be modified using techniques known in the art to change the glycosylation characteristics. Available techniques for producing antibodies with missing or reduced fucosylation characteristics include commercially available techniques (e.g., GlyMAXX (ProBiogen)) and methods (e.g., methods disclosed in WO2011 / 035884).

[0147] In some embodiments, anti-CD25 antibodies induce ADCC activity. Anti-CD25 antibodies exhibit ADCC activity on CD25+ target cells. "Antibody-dependent cell-mediated cytotoxicity" (ADCC) refers to a cell-mediated reaction in which non-specific cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, and macrophages) expressing Fc receptors (FcRs) recognize bound antibodies on target cells, resulting in target cell lysis. In some embodiments, anti-CD25 antibodies induce ADCP activity. "Antibody-dependent cell-mediated phagocytosis" (ADCP) refers to a cell-mediated reaction in which phagocytic cells (e.g., macrophages) expressing Fc receptors (FcRs) recognize bound antibodies on target cells, resulting in phagocytosis of target cells.

[0148] The anti-CD25 antibodies used in the present invention may act through ADCC and ADCP activities. ADCC and ADCP may be measured using assays known and available in the art.

[0149] In some embodiments of the present invention, the anti-CD25 antibody does not inhibit the binding of interleukin 2 (IL-2) to CD25. The "does not inhibit the binding of interleukin 2 to CD25" mentioned herein can be alternatively expressed as the anti-CD25 antibody being a non-IL-2 blocking antibody or a "non-blocking" antibody (relative to not blocking the binding of IL-2 to CD25 in the presence of the anti-CD25 antibody), that is, the antibody does not block the binding of interleukin 2 to CD25, and in particular does not inhibit interleukin 2 signaling in CD25-expressing cells. References to non-IL-2 blocking antibodies herein can be alternatively expressed as anti-CD25 antibodies that "do not inhibit the binding of interleukin 2 to CD25" or anti-CD25 antibodies that "do not inhibit IL-2 signaling". References to "non-blocking", "non-IL-2 blocking", "non-blocking" or "no blocking" and the like (relative to not blocking IL-2 binding to CD25 in the presence of an anti-CD25 antibody) include embodiments in which the anti-CD25 antibodies of the invention do not block IL-2 signaling through CD25. That is, the anti-CD25 antibodies inhibit less than 50% of IL-2 signaling compared to IL-2 signaling in the absence of the antibody. In specific embodiments of the invention described herein, the anti-CD25 antibodies inhibit less than about 50%, 40%, 35%, 30%, preferably less than about 25% of IL-2 signaling compared to IL-2 signaling in the absence of the antibody.

[0150] Some anti-CD25 antibodies can allow IL-2 to bind to CD25 but still block signaling through the CD25 receptor, and such antibodies may also be referred to as "non-blocking," "non-IL-2 blocking," "non-blocking," or "no blocking," etc. (relative to not blocking IL-2 signaling through CD25 in the presence of the anti-CD25 antibody). Non-IL-2 blocking anti-CD25 antibodies allow IL-2 to bind to CD25 to promote at least 50% of the signaling level through the CD25 receptor compared to signaling in the absence of the anti-CD25 antibody. In specific embodiments of the invention described herein, the anti-CD25 antibody inhibits IL-2 signaling by less than about 50%, 40%, 35%, 30%, preferably less than about 25%, compared to IL-2 signaling in the absence of the antibody.

[0151] IL-2 signaling through CD25 can be measured by methods such as those discussed in WO2018 / 167104 and known in the art. IL-2 signaling in the presence and absence of an anti-CD25 antibody agent can be compared under the same or substantially the same conditions.

[0152] In some embodiments, the level of phosphorylated STAT5 protein in cells can be measured using standard Stat-5 phosphorylation analysis to determine IL-2 signaling. For example, the Stat-5 phosphorylation analysis measuring IL-2 signaling can involve, in the presence of anti-CD25 antibodies, culturing PMBC cells at a concentration of 10ug / ml for 30 minutes, then adding different concentrations of IL-2 (e.g., 10U / ml or different concentrations of 0.25U / ml, 0.74U / ml, 2.22U / ml, 6.66U / ml or 20U / ml) for 10 minutes. The cells can then be permeabilized, and then the level of STAT5 protein can be measured by flow cytometry analysis of phosphorylated STAT5 peptides using fluorescently labeled antibodies. The IL-2 signaling blocking percentage can be calculated as follows: % blocking = 100 × [(% Stat5+ cell no antibody group-% Stat5+ cell 10ug / ml antibody group) / (% Stat5+ cell no antibody group).

[0153] Examples of non-blocking anti-CD25 antibodies are described in WO2018 / 167104, WO2019 / 175215, WO2019 / 175216, WO2019 / 175217, WO2019 / 175220, WO2019 / 17522, WO2019 / 175223, WO2019 / 17524, WO2019 / 17526, the contents of which are incorporated herein by reference in their entirety.

[0154] The anti-CD25 antibody can specifically bind to an epitope within the extracellular region of human CD25. In some embodiments, the antibody binds to an epitope different from the IL-2 binding site and does not block the binding of IL-2 to CD25.

[0155] As used herein, "epitope" refers to the portion of an antigen that is bound by an antibody or antigen-binding fragment. As is well known in the art, an epitope can be formed by contiguous amino acids (linear epitopes) or non-contiguous amino acids juxtaposed by the tertiary folding of a protein (conformational epitopes). Epitopes formed by contiguous amino acids are generally retained upon exposure to denaturing solvents, whereas epitopes formed by tertiary folding are generally lost upon treatment with denaturing solvents.

[0156] An epitope is conformational because it consists of parts of an antigen that are not covalently continuous but are close to each other in three-dimensional space when the antigen is in a related conformation. For example, for CD25, a conformational epitope is an epitope consisting of discontinuous amino acid residues in the extracellular domain of CD25; a linear epitope is an epitope consisting of continuous amino acid residues in the extracellular domain of CD25. Methods for determining the exact sequence and / or in particular amino acid residues of anti-CD25 antibody epitopes are known in the literature, including competition with peptides from antigen sequences for binding to CD25 sequences from different species (truncation and / or mutagenesis (e.g., by alanine scanning or other site-directed mutagenesis)), phage display-based screening, yeast presentation technology, or (co) crystallography. Methods for determining the spatial conformation of epitopes are also well known in the art, including, for example, X-ray crystallography and 2-D nuclear magnetic resonance. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed (1996). Thus, in some embodiments, an anti-CD25 antibody may recognize a conformational epitope.

[0157] In some embodiments, the anti-CD25 antibody binds to an epitope, wherein the epitope comprises one or more amino acid residues contained in one or more amino acid stretches selected from the group consisting of amino acids 150-163 of SEQ ID NO: 1 (YQCVQGYRALHRGP) (SEQ ID NO: 52), amino acids 166-186 of SEQ ID NO: 1 (SVCKMTHGKTRWTQPQLICTG) (SEQ ID NO: 53), amino acids 42-56 of SEQ ID NO: 1 (KEGTMLNCECKRGFR) (SEQ ID NO: 54), and amino acids 70-88 of SEQ ID NO: 1 (NSSHSSWDNQCQCTSSATR) (SEQ ID NO: 55). Preferably, the epitope comprises at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen or more amino acid residues contained in one or more amino acid stretches selected from the group consisting of amino acids 150-163 of SEQ ID NO: 1 (YQCVQGYRALHRGP) (SEQ ID NO: 52), amino acids 166-186 of SEQ ID NO: 1 (SVCKMTHGKTRWTQPQLICTG) (SEQ ID NO: 53), amino acids 42-56 of SEQ ID NO: 1 (KEGTMLNCECKRGFR) (SEQ ID NO: 54), and / or amino acids 70-88 of SEQ ID NO: 1 (NSSHSSWDNQCQCTSSATR) (SEQ ID NO: 55).

[0158] In some embodiments, the anti-CD25 antibody binds to an epitope of human CD25, wherein the epitope comprises at least one sequence selected from the group consisting of amino acids 150-158 (YQCVQGYRA) (SEQ ID NO: 56) of SEQ ID NO: 1, amino acids 176-180 (RWTQP) (SEQ ID NO: 57) of SEQ ID NO: 1, amino acids 42-56 (KEGTMLNCECKRGFR) (SEQ ID NO: 54) of SEQ ID NO: 1, and amino acids 74-84 (SSWDNQCQCTS) (SEQ ID NO: 58) of SEQ ID NO: 1. Such an antibody does not inhibit the binding of IL-2 to CD25.

[0159] In one embodiment, the anti-CD25 antibody binds to an epitope comprising the sequence of amino acids 70-84 of SEQ ID NO: 1 (NSSHSSWDNQCQCTS) (SEQ ID NO: 59).

[0160] Natural antibodies and immunoglobulins are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each heavy chain has a variable domain (V H ), followed by multiple constant domains. Each light chain has a variable domain (V L ), with a constant domain at the carboxyl terminus.

[0161] The variable region is capable of interacting with a structurally complementary antigen target and is characterized by differences in the amino acid sequence of antibodies with different antigenic specificities. The variable region of the heavy or light chain contains an amino acid sequence that is capable of specifically binding to the antigenic target. These sequences contain smaller sequences that are referred to as "hypervariable" because they have great variability between antibodies of different specificities. Such hypervariable regions are also referred to as "complementarity determining regions" or "CDR" regions.

[0162] These CDR regions explain the basic specificity of antibodies to specific antigenic determinant structures. CDR represents discontinuous amino acid sequence segments in the variable region, but no matter how the species, it has been found that the positions of these key amino acid sequences in the variable heavy chain region and the variable light chain region have similar positions to the amino acid sequences of the variable chains. For each heavy chain (H) and light chain (L), the variable heavy chain and light chain of all antibodies each have 3 CDR regions, each not adjacent to other regions (referred to as H1, H2, H3, L1, L2, L3). The CDR regions specified herein are defined according to Kabat (Kabat et al., 1977. J Biol Chem 252, 6609-6616).

[0163] In some embodiments, the anti-CD25 antibody is selected from the group consisting of:

[0164] (a) an antibody or antigen-binding fragment thereof comprising:

[0165] a heavy chain variable region comprising: a CDR-H1 comprising an amino acid sequence of any one of SEQ ID NOs: 2-5, a CDR-H2 comprising an amino acid sequence of any one of SEQ ID NOs: 6-11, and a CDR-H3 comprising an amino acid sequence of SEQ ID NO: 12, and

[0166] a light chain variable region comprising: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 13, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 14, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 15;

[0167] (b) an antibody or antigen-binding fragment thereof comprising:

[0168] a heavy chain variable region comprising: a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 23, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 24, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 25, and

[0169] a light chain variable region comprising: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 26, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 27, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 28; and

[0170] (c) an antibody or antigen-binding fragment thereof comprising:

[0171] a heavy chain variable region comprising: a CDR-H1 comprising an amino acid sequence of any one of SEQ ID NOs: 31-33, a CDR-H2 comprising an amino acid sequence of any one of SEQ ID NOs: 34-38, and a CDR-H3 comprising an amino acid sequence of SEQ ID NO: 39, and

[0172] The light chain variable region comprises: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 40, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 41, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 42.

[0173] In some embodiments, the anti-CD25 antibody is selected from the group consisting of:

[0174] (a) an antibody or antigen-binding fragment thereof comprising:

[0175] a heavy chain variable region comprising: a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 2, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 6, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 12, and

[0176] a light chain variable region comprising: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 13, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 14, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 15;

[0177] (b) an antibody or antigen-binding fragment thereof comprising:

[0178] a heavy chain variable region comprising: a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 2, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 7, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 12, and

[0179] a light chain variable region comprising: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 13, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 14, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 15;

[0180] (c) an antibody or antigen-binding fragment thereof comprising:

[0181] a heavy chain variable region comprising: a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 8, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 12, and

[0182] a light chain variable region comprising: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 13, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 14, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 15;

[0183] (d) an antibody or antigen-binding fragment thereof comprising:

[0184] a heavy chain variable region comprising: a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 2, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 9, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 12, and

[0185] a light chain variable region comprising: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 13, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 14, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 15;

[0186] (e) an antibody or antigen-binding fragment thereof comprising:

[0187] a heavy chain variable region comprising: a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 12, and

[0188] a light chain variable region comprising: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 13, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 14, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 15; and

[0189] (f) an antibody or antigen-binding fragment thereof comprising:

[0190] a heavy chain variable region comprising: a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 5, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 11, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 12, and

[0191] a light chain variable region comprising: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 13, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 14, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 15;

[0192] In some embodiments, the anti-CD25 antibody is selected from the group consisting of:

[0193] (a) an antibody comprising: a heavy chain variable region comprising the amino acid sequence of any one of SEQ ID NOs: 16-21 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 22;

[0194] (b) an antibody comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 29 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 30; and

[0195] (c) An antibody comprising: a heavy chain variable region comprising the amino acid sequence of any one of SEQ ID NOs: 43-48 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 49.

[0196] In some embodiments, the anti-CD25 antibody is selected from the group consisting of:

[0197] (a) an antibody comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 16 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 22;

[0198] (b) an antibody comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 22;

[0199] (c) an antibody comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 18 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 22;

[0200] (d) an antibody comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 22;

[0201] (e) an antibody comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 20 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 22;

[0202] (f) an antibody comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 21 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 22; and

[0203] (g) an antibody comprising: a heavy chain variable region comprising a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any one of SEQ ID NOs: 16-21 and a light chain variable region comprising a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22.

[0204] The following table provides the SEQ ID NOs for the complementarity determining regions (HCDR1-3 and LCDR1-3) and the heavy and light chain variable regions of exemplary antibodies:

[0205] Table 1:

[0206]

[0207] Such antibodies are further described in WO2019 / 175216, WO2019 / 175217 and WO2019 / 1175222. The contents thereof are incorporated herein by reference.

[0208] The antibody referred to herein as aCD25-a-686 may also be referred to as RG6292. In a preferred embodiment, the anti-CD25 antibody is RG6292. The anti-CD25 antibody referred to as "RG6292" is an afucosylated human IgG1 monoclonal antibody. RG6292 comprises a heavy chain sequence having the sequence of SEQ ID NO: 50 and a light chain sequence having the sequence of SEQ ID NO: 51.

[0209] Such antibodies are referred to as "non-IL-2 blocking" antibodies and do not inhibit the binding of IL-2 to CD25.

[0210] Variants of the antibodies defined above may also be used. Variants of antibodies include antibodies in which the sequence of each CDR sequence comprises an amino acid sequence having the following characteristics:

[0211] (i) is at least 85% identical to, and / or

[0212] (ii) has one, two or three amino acid substitutions relative to SEQ ID NO: 2-15, 23-28 or 31-42.

[0213] Antibody variants also include antibodies in which the sequence of each of the light chain and heavy chain comprises an amino acid sequence having the following characteristics:

[0214] (i) is at least 80% identical to, and / or

[0215] (ii) has one, two, three, four or five amino acid substitutions relative to SEQ ID NO: 16-22, 29-30 or 43-51.

[0216] For example, one embodiment of the present invention provides an anti-CD25 antibody for treating cancer, wherein the anti-CD25 antibody is selected from the group consisting of:

[0217] a) an antibody or an antigen-binding fragment thereof, comprising:

[0218] - a heavy chain variable region comprising: a CDR-H1 comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 2-5; a CDR-H2 comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 6-11; and a CDR-H3 comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 12, and

[0219] - a light chain variable region comprising: a CDR-L1 comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 13; a CDR-L2 comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 14; and a CDR-H3 comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 15;

[0220] b) an antibody or an antigen-binding fragment thereof, comprising:

[0221] - a heavy chain variable region comprising: a CDR-H1 comprising an amino acid sequence having one, two or three amino acid substitutions relative to any one of SEQ ID NOs: 2-5; a CDR-H2 comprising an amino acid sequence having one, two or three amino acid substitutions relative to any one of SEQ ID NOs: 6-11; and a CDR-H3 comprising an amino acid sequence having one, two or three amino acid substitutions relative to SEQ ID NO: 12, and

[0222] - a light chain variable region comprising: a CDR-L1 comprising an amino acid sequence having one, two or three amino acid substitutions relative to SEQ ID NO: 13; a CDR-L2 comprising an amino acid sequence having one, two or three amino acid substitutions relative to SEQ ID NO: 14; and a CDR-H3 comprising an amino acid sequence having one, two or three amino acid substitutions relative to SEQ ID NO: 15, and

[0223] c) an antibody or an antigen-binding fragment thereof, comprising:

[0224] - A heavy chain variable region comprising:

[0225] i) an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 16-21; or

[0226] ii) an amino acid sequence having one, two, three, four or five amino acid substitutions relative to SEQ ID NOs: 16-21;

[0227] and

[0228] - A light chain variable region comprising:

[0229] i) an amino acid sequence that has at least 80% sequence identity to SEQ ID NO: 22; or

[0230] ii) an amino acid sequence having one, two, three, four or five amino acid substitutions relative to SEQ ID NO:22.

[0231] Percentage (%) identity as known in the art is the relationship between two or more polypeptide sequences or two or more polynucleotide sequences, which is determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences (as the case may be), which is determined by the matching between such sequence strings. Although there are many methods for measuring the identity between two polypeptide sequences or two polynucleotide sequences, the methods usually used to determine identity are codified in computer programs. Preferred computer programs for determining the identity between two sequences include, but are not limited to, the GCG program package (Devereux, et al., Nucleic Acids Research, 12, 387 (1984)), BLASTP, BLASTN and FASTA (Atschul et al., J. Molec. Biol. 215, 403 (1990)). The percent identity of two amino acid sequences or two nucleic acid sequences is determined by aligning the sequences for optimal comparison purposes (e.g., gaps can be introduced in the first sequence to optimally align with the sequences) and comparing the amino acid residues or nucleotides at corresponding positions. The "optimal alignment" is the alignment of the two sequences that achieves the highest percent identity. The percent identity is determined by the number of identical amino acid residues or nucleotides in the compared sequences (i.e., % identity = number of identical positions / total number of positions x 100). In general, unless otherwise specified or implied by the context, the % identity mentioned herein refers to the % identity over the entire length of the molecule.

[0232] The term "antibody" as used herein refers to both intact immunoglobulin molecules and fragments thereof that contain an antigen binding site, including polyclonal, monoclonal, genetically engineered and other modified forms of antibodies, including but not limited to chimeric antibodies, humanized antibodies, heteroconjugates and / or multispecific antibodies (e.g., bispecific antibodies, diabodies, triabodies and tetrabodies) and antigen-binding fragments of antibodies, including, for example, Fab', F(ab')2, Fab, Fv, rIgG, polypeptide-Fc fusions, single-chain variants (scFv fragments, VHH, Shark single domain antibodies, single chain or tandem diabodies VHH, Mini-antibodies, In some embodiments, an antibody may lack covalent modifications (e.g., attachment of glycans) that it would have if it were naturally produced. In some embodiments, an antibody may contain covalent modifications (e.g., attachment of glycans, detectable moieties, therapeutic moieties, catalytic moieties, or other chemical groups that provide improved antibody stability or administration, such as polyethylene glycol). In some embodiments, an antibody may be in the form of a masked antibody (e.g., ). The masked antibody may comprise a blocking or "masking" peptide that specifically binds to the antigen binding surface of the antibody and interferes with the antigen binding of the antibody. The masking peptide is linked to the antibody by a cleavable linker (e.g., a protease). The linker is selectively cleaved in the desired environment (i.e., the tumor environment) to dissociate the masking / blocking peptide, allowing antigen binding to occur in the tumor, thereby limiting potential toxicity issues. "Antibody" may also refer to camelid antibodies (heavy chain antibodies only) and antibody-like molecules, such as anticalin (Skerra (2008) FEBS J 275, 2677-83). In some embodiments, the antibody is polyclonal or oligoclonal, which is produced as a group of antibodies, each associated with a single antibody sequence and binding to more or less different epitopes within the antigen (e.g., different epitopes within the extracellular domain of human CD25 associated with different reference anti-human CD25 antibodies, or different epitopes of FasL). As described in the literature, polyclonal or oligoclonal antibodies can be provided in the form of a single preparation for medical use (Kearns JD et al., 2015. Mol Cancer Ther. 14: 1625-36).

[0233] The antibodies used in the present invention may be monospecific, bispecific or multispecific. A "multispecific antibody" may be specific for different epitopes of a target antigen or polypeptide, or may contain antigen binding domains that are specific for more than one target antigen or polypeptide. In some embodiments of the present invention, the antibody is monospecific. In some embodiments, the antibody binds to CD25 or FasL in a monovalent manner (i.e., the ratio of one antibody to one CD25 molecule or one FasL molecule). In further embodiments, the antibody is a monospecific bivalent antibody, i.e., the antibody binds to CD25 at a ratio of one antibody to two CD25 molecules, or binds to FasL at a ratio of one antibody to two FasL molecules.

[0234] In some embodiments of the invention, the antibody is monoclonal. The antibody may additionally or alternatively be a humanized antibody or a human antibody. In further embodiments, the antibody is a human antibody, or in any case an antibody with a form and characteristics that allow it to be used and administered in a human subject.

[0235] "Monoclonal antibody" as used herein is not limited to antibodies produced by hybridoma technology. The term "monoclonal antibody" refers to an antibody derived from a single clone, including any eukaryotic, prokaryotic or phage clone, rather than from the method of its production.

[0236] As used herein, "human antibodies" refer to antibodies having variable regions in which the framework and CDR regions are derived from human germline immunoglobulin sequences. In addition, if the antibody contains a constant region, the constant region is also derived from human germline immunoglobulin sequences. The human antibodies of the present invention may include amino acid residues that are not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or by somatic mutation in vivo).

[0237] Antibodies (Ab) and immunoglobulins (Ig) are glycoproteins with the same structural features. Immunoglobulins can be from any class, such as IgA, IgD, IgG, IgE or IgM. Immunoglobulins can have any subclass, such as IgG1, IgG2, IgG3 or IgG4. In a preferred embodiment of the present invention, the anti-CD25 antibody is from the IgG class, preferably the IgG1 subclass. In one embodiment, the anti-CD25 antibody is from the human IgG1 subclass. In a preferred embodiment of the present invention, the anti-FasL antibody is from the IgG class, preferably the IgG1 subclass. In one embodiment, the anti-FasL antibody is from the human IgG1 subclass.

[0238] Treg cell depletion therapy can be administered in conjunction with cancer vaccines. Cancer vaccines are known in the art. "Cancer vaccine" as used herein refers to a therapeutic cancer vaccine administered to a cancer patient and intended to eliminate cancer cells by enhancing the patient's own immune response. In particular, cancer vaccines will be able to produce a tumor antigen-specific response. The selected cancer vaccine will depend on the type of cancer to be treated. Cancer vaccines include, but are not limited to, peptide-based vaccines, whole cell vaccines, dendritic cell vaccines, and DNA vaccines.

[0239] In one embodiment, the cancer vaccine administered according to the present invention is a cellular immunotherapy expressing a cytokine.

[0240] As used herein, the term "cytokine-expressing cellular immunotherapy" refers to a composition comprising a population of cells that have been genetically modified to express a cytokine (e.g., GM-CSF). Such "cytokine-expressing cellular immunotherapy" cells comprise a cytokine encoding DNA sequence operably linked to expression and control elements such that the cells express the cytokine. These cells are typically tumor cells that have been irradiated to prevent further cell division. These cells may be autologous (patient-specific) or allogeneic (non-patient-specific) to the patient being treated.

[0241] In one embodiment of the present invention, the cytokine-expressing cellular immunotherapy comprises tumor cells expressing GM-CSF. For example, it can be a cancer vaccine called GVAX. GVAX contains irradiated tumor cells secreting GM-CSF, which activates myeloid cells and makes them mature.

[0242] In the uses and methods described herein, Fas axis antagonists, anti-FasL antibodies, Treg cell depletion therapy, anti-CD25 antibodies and cancer vaccines are each administered in a therapeutically effective amount. As used herein, the term "therapeutically effective amount" refers to an amount (of a pharmaceutical agent or pharmaceutical composition) sufficient to treat such diseases and / or conditions when administered to a population suffering from or susceptible to a disease and / or condition according to a therapeutic dosing regimen. A therapeutically effective amount is an amount that reduces the incidence and / or severity of one or more symptoms of a disease, disorder and / or condition, stabilizes and / or delays its onset according to a treatment regimen. It should be understood by those of ordinary skill in the art that a "therapeutically effective amount" does not actually require successful treatment to be achieved in a particular subject.

[0243] The selection of an appropriate dosage of the antibody will be within the capabilities of those skilled in the art. For example, 0.01, 0.1, 0.3, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40 or 50 mg / kg. In some embodiments, this amount is a unit dosage (or its entire portion) suitable for administration according to a dosage regimen that has been determined to be associated with a desired or beneficial outcome when applied to a relevant population (i.e., using a therapeutic dosage regimen). The dosage may also vary due to the route of administration, treatment cycle, or subsequent dose escalation regimen, which can be used to determine the maximum tolerated dose and dose-limiting toxicity (if any) associated with administering an antibody or cancer vaccine at an increased dose.

[0244] In some embodiments of the invention, each component is administered multiple times in a treatment regimen. In some embodiments, a dosing regimen may include a first administration of a component in a first dosage, followed by one or more additional administrations in a second dosage that is the same as the first dosage. Alternatively, different administrations of each component in a dosing regimen have different dosages. In some embodiments, a dosing regimen includes a first administration in a first dosage, followed by one or more additional administrations in a second dosage that is different from the first dosage. In some embodiments, different antibodies may be administered in different dosages. Alternatively, different antibodies are administered in substantially the same dosage. In some embodiments, the same anti-CD25 antibody, anti-FasL antibody, and cancer vaccine are used for each administration. Alternatively, different anti-CD25 antibodies and anti-FasL antibodies, such as different Fas axis antagonists, may be used as part of a treatment regimen.

[0245] The antibody and cancer vaccine according to any aspect of the present invention can be in the form of a pharmaceutical composition that further comprises a pharmaceutically acceptable carrier, diluent or excipient. These compositions include, for example, liquid, semisolid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersants or suspensions, tablets, pills or liposomes. In some embodiments, the preferred form may depend on the intended mode of administration and / or therapeutic application. The pharmaceutical composition containing the antibody can be administered by any appropriate method known in the art, including but not limited to oral, mucosal, inhalation, topical, buccal, nasal, rectal or parenteral (e.g., intravenous, infusion, intratumoral, intranodular, subcutaneous, intraperitoneal, intramuscular, intradermal, transdermal, or other types of administration involving physical destruction of the tissue of the object and administration of the pharmaceutical composition through a rupture in the tissue). For example, this preparation can be in the form of an injectable or infusible solution suitable for intradermal, intratumoral or subcutaneous administration or intravenous infusion. Administration can involve continuous administration (e.g., perfusion) at least in a selected time period.

[0246] In some embodiments, the antibody can be prepared with a carrier that protects it from rapid release and / or degradation, such as a controlled release formulation, such as an implant, a transdermal patch, and a microencapsulated delivery system. Biodegradable, biocompatible polymers can be used.

[0247] It will be appreciated by those skilled in the art that, for example, the route of delivery (e.g., oral, intravenous, subcutaneous, intratumoral, etc.) may affect the dosage, and / or the required dosage may affect the route of delivery. For example, when the purpose is to have a particularly high concentration of a certain agent in a particular part or position (e.g., intratumoral), concentrated delivery (e.g., intratumoral delivery in this example) may be necessary and / or useful. Other factors to be considered when optimizing the route and / or dosing schedule for a given therapeutic regimen may include, for example, the specific cancer being treated (e.g., type, stage, location, etc.), the clinical condition of the subject (e.g., age, overall health, etc.), and other factors known to medical practitioners.

[0248] Each component in the combination used according to the present invention should be formulated for separate administration. The pharmaceutical composition of each component should generally be sterile and stable under manufacturing and storage conditions. The composition can be formulated into a solution, microemulsion, dispersion, liposome or other ordered structure suitable for high drug concentration. A sterile injectable solution can be prepared by incorporating the required amount of antibody with a combination of the ingredients listed above or the ingredients listed above (as required) into an appropriate solvent and then filtering and sterilizing. Preparations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release preparations or biodegradable preparations discussed herein. Nontoxic parenteral acceptable diluents or solvents can be used to prepare sterile injection preparations. Each pharmaceutical composition used according to the present invention can include pharmaceutically acceptable dispersants, wetting agents, suspending agents, isotonic agents, coating agents, antibacterial and antifungal agents, carriers, excipients, salts or stabilizers, which are nontoxic to the subject at the dosage and concentration used. Preferably, such a composition may also comprise a pharmaceutically acceptable carrier or excipient for treating cancer that is compatible with a given method and / or site of administration, such as for parenteral (e.g., subcutaneous, intradermal or intravenous injection), intratumoral or peritumoral administration.

[0249] Another aspect of the present invention provides a kit for treating cancer. The kit comprises at least two active components, wherein the kit comprises:

[0250] a) a first composition comprising a Treg cell depletion therapy; and

[0251] b) a second composition comprising a Fas axis antagonist,

[0252] And optionally, instructions for a combination therapy for cancer treatment using the composition. The combination therapy may include administering Treg cell depletion therapy and Fas axis antagonists according to the dosing regimen described in the first aspect and other aspects of the present invention. Specifically, the dosing regimen may include administering Fas axis antagonists after Treg cell depletion therapy. The kit may also include additional active ingredients, c) a third composition comprising a cancer vaccine.

[0253] The Treg cell depletion therapy, Fas axis antagonist, anti-CD25 antibody, anti-FasL antibody, cancer vaccine and administration and treatment regimen of all other aspects of the present invention may be as described in the first aspect of the present invention.

[0254] Aspects and embodiments described herein using the term "comprising" may include other features or steps within the scope. It should also be understood that aspects and embodiments described as "comprising" also describe aspects and embodiments in which the term "comprising" is replaced by the term "consisting essentially of" or "consisting of".

[0255] The phrase "selected from the group comprising" may be replaced with the phrase "selected from the group consisting of" anywhere herein, and vice versa.

[0256] A set of clauses defining the present invention and its preferred aspects and embodiments is as follows:

[0257] 1. A method for treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of each of a Treg cell depletion therapy and a Fas axis antagonist.

[0258] 2. The method according to clause 2, wherein the Treg depletion therapy comprises administering a therapeutically effective amount of an anti-CD25 antibody.

[0259] 3. The method according to clause 1 or 2, wherein the method further comprises administering a cancer vaccine.

[0260] 4. The method according to any one of clauses 1 to 3, wherein the Fas axis antagonist is an anti-FasL antibody.

[0261] 5. The method according to any one of clauses 1 to 4, comprising administering to the subject a therapeutically effective amount of each of an anti-CD25 antibody, an anti-FasL antibody and a cancer vaccine.

[0262] 6. The method according to clause 5, wherein the anti-CD25 antibody, anti-FasL antibody and cancer vaccine are administered separately.

[0263] 7. The method according to clause 6, comprising administering the anti-FasL antibody after administering the anti-CD25 antibody and the cancer vaccine.

[0264] 8. The method according to any one of clauses 5 to 7, comprising administering an anti-FasL antibody after depletion of Treg cells in the subject by administration of an anti-CD25 antibody.

[0265] 9. A method according to any one of clauses 5 to 8, wherein the method comprises administering to the subject an anti-CD25 antibody, followed by administration of a cancer vaccine, and then administration of an anti-FasL antibody.

[0266] 10. A method according to any one of clauses 5 to 9 comprising administering multiple doses of anti-CD25 antibody and anti-FasL antibody.

[0267] 11. The method according to clause 10, comprising administering a first dose of anti-FasL antibody after administering at least two doses of anti-CD25 antibody.

[0268] 12. The method according to any one of clauses 10 or 11, wherein each administration of anti-FasL antibody is administered within 20 days of administration of anti-CD25 antibody.

[0269] 13. The method according to any one of clauses 10 to 12, wherein each administration of anti-FasL antibody is administered after administration of an anti-CD25 antibody.

[0270] 14. The method according to clause 13, wherein the anti-FasL antibody is administered after the administration of the anti-CD25 antibody, which is repeated a plurality of times, with the interval between administrations of the anti-CD25 antibody being at least one week.

[0271] 15. A method according to any one of clauses 5 to 14, comprising administering multiple doses of the cancer vaccine.

[0272] 16. The method according to clause 15, wherein administering multiple doses of the cancer vaccine comprises administering a dose of the cancer vaccine between each dose of the anti-CD25 antibody and the anti-FasL antibody.

[0273] 17. The method according to clause 16, comprising:

[0274] a) administering an anti-CD25 antibody;

[0275] b) administering a cancer vaccine, optionally, wherein administering the cancer vaccine comprises administering multiple doses of the cancer vaccine;

[0276] c) administering anti-CD25 antibodies;

[0277] d) optionally administering a cancer vaccine; and

[0278] e) administering a Fas axis antagonist,

[0279] Wherein the method comprises repeating steps c) to e) over a treatment period of at least 7 days.

[0280] 18. The method according to any one of clauses 5 to 17, wherein all administrations of anti-CD25 antibody are with the same anti-CD25 antibody.

[0281] 19. The method according to any one of clauses 5 to 18, wherein the cancer is a CD25 positive cancer.

[0282] 20. The method according to any one of clauses 5 to 19, wherein the cancer is a blood cancer.

[0283] 21. The method according to any one of clauses 5 to 20, wherein the cancer is a solid tumor.

[0284] 22. The method according to any one of clauses 5 to 21, wherein the cancer is selected from acute myeloid leukemia, diffuse large cell B-cell lymphoma, melanoma, non-small cell lung cancer, renal cancer, ovarian cancer, bladder cancer, sarcoma and colorectal cancer.

[0285] 23. The method according to clause 22, wherein the cancer is acute myeloid leukemia or diffuse large B-cell lymphoma.

[0286] 24. The method according to clause 22, wherein the cancer is melanoma.

[0287] 25. The method according to any one of clauses 5 to 24, wherein the anti-CD25 antibody inhibits IL-2 signaling through CD25 by less than 50% compared to IL-2 signaling in the absence of the anti-CD25 antibody.

[0288] 26. The method according to clause 25, wherein the anti-CD25 antibody inhibits IL-2 signaling through CD25 by less than 25% compared to IL-2 signaling in the absence of the anti-CD25 antibody.

[0289] 27. The method according to any one of clauses 5 to 26, wherein the anti-CD25 antibody is selected from the group consisting of:

[0290] (a) Antibodies, including:

[0291] a heavy chain variable region comprising: a CDR-H1 comprising an amino acid sequence of any one of SEQ ID NOs: 2-5, a CDR-H2 comprising an amino acid sequence of any one of SEQ ID NOs: 6-11, and a CDR-H3 comprising an amino acid sequence of SEQ ID NO: 12, and

[0292] a light chain variable region comprising: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 13, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 14, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 15;

[0293] (b) Antibodies, including:

[0294] a heavy chain variable region comprising: a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 23, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 24, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 25, and

[0295] a light chain variable region comprising: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 26, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 27, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 28; and

[0296] (c) Antibodies, including:

[0297] a heavy chain variable region comprising: a CDR-H1 comprising an amino acid sequence of any one of SEQ ID NOs: 31-33, a CDR-H2 comprising an amino acid sequence of any one of SEQ ID NOs: 34-38, and a CDR-H3 comprising an amino acid sequence of SEQ ID NO: 39, and

[0298] The light chain variable region comprises: a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 40, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 41, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 42.

[0299] 28. The method according to any one of clauses 5 to 27, wherein the anti-CD25 antibody is RG6292.

[0300] 29. A method according to any one of clauses 5 to 28, wherein the anti-CD25 antibody binds to an epitope comprising at least one sequence selected from amino acids 150-158 of SEQ ID NO: 1, amino acids 176-180 of SEQ ID NO: 1, amino acids 42-56 of SEQ ID NO: 1 and amino acids 74-84 of SEQ ID NO: 1.

[0301] 30. The method according to clause 29, wherein the anti-CD25 antibody binds to an epitope comprising amino acids 70-84 of SEQ ID NO: 1.

[0302] 31. The method according to any one of clauses 5 to 30, wherein the cancer vaccine is a cellular immunotherapy expressing cytokines.

[0303] 32. The method according to any one of clause 31, wherein the cytokine-expressing cellular immunotherapy comprises irradiated GM-CSF-expressing tumor cells.

[0304] 33. A Treg cell depletion therapy for treating cancer, wherein the Treg cell depletion therapy antibody is used in combination with a Fas axis antagonist and an optional cancer vaccine.

[0305] 34. An anti-CD25 antibody for treating cancer, wherein the anti-CD25 antibody is used in combination with an anti-FasL antibody and optionally a cancer vaccine.

[0306] 35. A Fas axis antagonist for treating cancer, wherein the Fas axis antagonist is used in combination with Treg cell depletion therapy and optionally a cancer vaccine.

[0307] 36. An anti-FasL antibody for use in treating cancer, wherein the anti-FasL antibody is used in combination with an anti-CD25 antibody and optionally a cancer vaccine.

[0308] 37. A cancer vaccine for treating cancer, wherein the cancer vaccine is used in combination with a Fas axis antagonist and Treg cell depletion therapy.

[0309] 38. The cancer vaccine for use according to clause 37, wherein the Fas axis antagonist is an anti-FasL antibody and the Treg cell depletion therapy is an anti-CD25 antibody.

[0310] 39. A combination of Treg cell depletion therapy and a Fas axis antagonist for treating cancer, wherein the Treg cell depletion therapy and the Fas axis antagonist are administered separately, simultaneously or sequentially.

[0311] 40. The combination for use according to clause 39, wherein the Treg cell depletion therapy comprises an anti-CD25 antibody.

[0312] 41. The combination for use according to clause 40, further comprising a cancer vaccine.

[0313] 42. A combination for use according to clause 41, wherein the combination comprises: a) a first component comprising an anti-CD25 antibody; b) a second component comprising a Fas axis antagonist; and c) a third component comprising a cancer vaccine, the first component, the second component and the third component being administered separately, simultaneously or sequentially.

[0314] 43. The combination for use according to clause 42, wherein the Fas axis antagonist is administered after the anti-CD25 antibody and the cancer vaccine.

[0315] 44. The combination for use according to any one of clauses 42 to 43, wherein the Fas axis antagonist is administered after depletion of Treg cells in the subject by administration of an anti-CD25 antibody.

[0316] 45. The combination for use according to any one of clauses 42 to 44, wherein the subject is administered an anti-CD25 antibody, followed by a cancer vaccine, and then a Fas axis antagonist.

[0317] 46. ​​Combination for use according to any one of clauses 42 to 45, wherein the treatment comprises administering multiple doses of the anti-CD25 antibody.

[0318] 47. Combination for use according to any one of clauses 42 to 46, wherein the treatment comprises administering multiple doses of the Fas axis antagonist.

[0319] 48. Combination for use according to any one of clauses 42 to 47, wherein the treatment comprises administering multiple doses of the cancer vaccine.

[0320] 49. The combination for use according to any one of clauses 42 to 48, wherein administration comprises:

[0321] Anti-CD25 antibody was administered first;

[0322] subsequently administering one or more doses of the cancer vaccine;

[0323] One or more alternating administrations of the anti-CD25 antibody and the Fas axis antagonist are subsequently administered, wherein each further administration of the anti-CD25 antibody is administered prior to the Fas axis antagonist.

[0324] 50. The combination for use according to clause 49, wherein the combination of administration of the Fas axis antagonist and further administration of the anti-CD25 antibody is administered repeatedly over a treatment cycle of at least 7 days.

[0325] 51. The combination for use according to any one of clauses 49 or 50, wherein the administration of one or more alternating doses of an anti-CD25 antibody and a Fas axis antagonist further comprises the administration of one or more doses of a cancer vaccine, wherein each further dose of the anti-CD25 antibody and the cancer vaccine is administered prior to the administration of the Fas axis antagonist.

[0326] 52. The combination for use according to any one of clauses 42 to 51, wherein the anti-CD25 antibody inhibits IL-2 signalling through CD25 by less than 50% compared to IL-2 signalling in the absence of the anti-CD25 antibody.

[0327] 53. The combination for use according to any one of clauses 42 to 52, wherein the anti-CD25 antibody is an anti-CD25 antibody as defined in any one of clauses 25 to 30.

[0328] 54. The combination for use according to any one of clauses 39 to 53, wherein the cancer vaccine is a cytokine-expressing cellular immunotherapy, preferably wherein the cytokine-expressing cellular immunotherapy comprises tumor cells expressing GM-CSF.

[0329] 55. The combination for use according to any one of clauses 42 to 54, wherein the Fas axis antagonist is an anti-FasL antibody.

[0330] 56. A combination of an anti-CD25 antibody, an anti-FasL antibody and a cancer vaccine for use in treating cancer, wherein the anti-CD25 antibody, the anti-FasL antibody and the cancer vaccine are administered separately, simultaneously or sequentially.

[0331] 57. A method for treating or preventing recurrence of cancer in a subject, wherein the subject has received Treg cell depletion therapy for treating cancer, wherein the method comprises administering to the subject at least one dose of a Fas axis antagonist (e.g., an anti-FasL antibody) following the Treg cell depletion therapy.

[0332] 58. The method of claim 57, wherein the Fas axis antagonist is an anti-FasL antibody.

[0333] 59. The method according to clause 57 or 58, wherein the Treg cell depletion therapy comprises administering an anti-CD25 antibody.

[0334] 60. The method according to any one of clauses 57 to 59, wherein the method further comprises administering a cancer vaccine.

[0335] 61. A method according to any one of clauses 57 to 60 comprising administering a Fas axis antagonist in conjunction with a further administration of an anti-CD25 antibody.

[0336] 62. The method according to clause 61, wherein each administration of the Fas axis antagonist is administered after each further administration of the anti-CD25 antibody.

[0337] 63. A method according to clause 62, wherein the method comprises, in the following order:

[0338] a) administering an anti-CD25 antibody;

[0339] b) administering a cancer vaccine, optionally, wherein administering the cancer vaccine comprises administering multiple doses of the cancer vaccine;

[0340] c) administering anti-CD25 antibodies;

[0341] d) administering cancer vaccines; and

[0342] e) administering a Fas axis antagonist,

[0343] Wherein the method comprises repeating steps c) to e) over a treatment period of at least 7 days.

[0344] 64. A method of treating cancer in a subject, comprising administering to the subject:

[0345] a) priming administration of Treg cell depletion therapy; and

[0346] b) Administration of a Fas axis antagonist and boost administration of Treg cell depletion therapy, wherein the boost administration of Treg cell depletion therapy is administered before the Fas axis antagonist.

[0347] 65. The method according to clause 64, wherein the Fas axis antagonist is an anti-FasL antibody.

[0348] 66. The method according to any of clauses 64 or 65, comprising administering multiple doses of a Fas axis antagonist and an anti-CD25 antibody, wherein each dose of the Fas axis antagonist is administered after a booster dose of Treg cell depletion therapy.

[0349] 67. A method according to any one of clauses 64 to 66, comprising administering multiple doses of the Fas axis antagonist and booster doses of Treg cell depletion therapy, wherein at least 7 days are separated between booster doses of Treg cell depletion therapy.

[0350] 68. A method according to any one of clauses 64 to 67, comprising administering a priming dose of a cancer vaccine in combination with a priming dose of a Treg cell depletion therapy.

[0351] 69. The method according to clause 68, wherein the priming administration of the cancer vaccine is administered after the priming administration of the Treg cell depletion therapy and before the boosting administration of the Treg cell depletion therapy.

[0352] 70. The method according to clause 69, comprising administering booster doses of the cancer vaccine, wherein each booster dose of the cancer vaccine is administered in conjunction with each booster dose of the Treg cell depletion therapy.

[0353] 71. A method according to clause 70, wherein the method comprises:

[0354] a) administering a priming dose of Treg cell depletion therapy;

[0355] b) administering one or more doses of a cancer vaccine;

[0356] c) administering a booster dose of Treg cell depletion therapy;

[0357] d) optionally administering a cancer vaccine booster; and

[0358] e) administration of a Fas axis antagonist,

[0359] Wherein the method comprises repeating steps c) to e) over a treatment period of at least 7 days.

[0360] 72. The method according to any one of clauses 64 to 71, wherein the Treg cell depletion therapy comprises an anti-CD25 antibody.

[0361] 73. The method according to clause 72, wherein the anti-CD25 antibody is an anti-CD25 antibody as defined in any one of clauses 25 to 30.

[0362] 74. A method according to any one of clauses 60 to 63 or 68 to 73, wherein the cancer vaccine is a cancer vaccine as defined in any one of clauses 31 to 32.

[0363] 75. A Fas axis antagonist for use in treating or preventing recurrence of cancer in a subject, wherein the subject has received Treg cell depletion therapy for treating cancer, and wherein the Fas axis antagonist is administered to the subject subsequent to the Treg cell depletion therapy.

[0364] 76. A Fas axis antagonist for use according to clause 75, wherein the Fas axis antagonist is an anti-FasL antibody.

[0365] 77. A Treg cell depletion therapy for treating or preventing cancer recurrence in a subject, wherein the Treg cell depletion therapy is used in combination with at least one administration of a Fas axis antagonist, wherein the Fas axis antagonist is administered to the subject after the Treg cell depletion therapy.

[0366] 78. Treg cell depletion therapy for use according to clause 77, wherein the subject has received initial Treg cell depletion therapy to treat cancer.

[0367] 79. Treg cell depletion therapy for use according to any one of clauses 77 or 78, wherein the Fas axis antagonist is an anti-FasL antibody.

[0368] 80. A combination of a) a priming administration of Treg cell depletion therapy; b) a boosting administration of Treg cell depletion therapy, and c) administration of a Fas axis antagonist for treating or preventing cancer recurrence in a subject, wherein the priming administration of Treg cell depletion therapy and the first boosting administration of Treg cell depletion therapy are administered prior to the Fas axis antagonist.

[0369] 81. The combination for use according to clause 80, further comprising d) a priming administration of a cancer vaccine, wherein the priming administration of the cancer vaccine is administered between the Treg cell depletion therapy and the first boosting administration of the Treg cell depletion therapy.

[0370] 82. The combination for use according to any one of clauses 80 or 81, wherein the treatment comprises repeated administration of booster doses of Treg cell depletion therapy and a Fas axis antagonist, wherein each booster dose of Treg cell depletion therapy is administered prior to each dose of the Fas axis antagonist.

[0371] 83. The combination for use according to clause 82, further comprising e) booster administration of a cancer vaccine, wherein each booster administration of the cancer vaccine is administered between each booster administration of the Treg cell depletion therapy and each administration of the Fas axis antagonist.

[0372] 84. The combination for use according to any one of clauses 80 to 83, wherein the Treg cell depletion therapy comprises an anti-CD25 antibody and the Fas axis antagonist is an anti-FasL antibody.

[0373] 85. The combination for use according to any one of clauses 81 or 83, wherein the cancer vaccine is a cytokine-expressing cellular immunotherapy, preferably wherein the cytokine-expressing cellular immunotherapy comprises tumor cells expressing GM-CSF.

[0374] 86. T cell depletion therapy for use according to any one of clauses 33 or 77 to 79, an anti-CD25 antibody for use according to clause 34, a Fas axis antagonist for use according to any one of clauses 35, 75-76, an anti-FasL antibody for use according to clause 36, a cancer vaccine for use according to any one of clauses 37 or 38, or a combination for use according to any one of clauses 39-56 or 80-85, wherein the cancer is a solid tumor.

[0375] 87. A kit comprising:

[0376] a) a first composition comprising a Treg cell depletion therapy; and

[0377] b) a second composition comprising a Fas axis antagonist,

[0378] And optionally, instructions for using the composition for combination therapy for treating cancer.

[0379] 88. The kit according to clause 87, further comprising c) a third composition comprising a cancer vaccine.

[0380] It should also be understood that, unless the context otherwise requires, this application discloses all combinations of any of the above aspects and embodiments with each other. Similarly, unless the context otherwise requires, this application discloses all combinations of preferred and / or optional features, whether individually or together with any other aspects.

[0381] The present invention will now be further described by the following examples and with reference to the accompanying drawings, which are intended to help those of ordinary skill in the art to practice the present invention and are not intended to limit the scope of the present invention in any way.

[0382] Example

[0383] Mouse

[0384] C57BL / 6 mice (6-8 weeks old female) were provided by Charles River Laboratories. All animal studies were performed under ethical approval and regulations of University College London and the UK Home Office.

[0385] Cell lines and tissue culture

[0386] Highly tumorigenic and weakly immunogenic cell line B16 / BL6 mouse melanoma cells were obtained from Dr. IJ Fidler of the University of Texas MD Anderson Cancer Center (Houston, TX). Therapy was performed using GM-CSF (GVAX) expressing B16 / BL6. Both cell lines have been described previously (Van Elsas et al., 1999, J Exp Med vol. 190 (3) p355-366). B16 / BL6 and GVAX cells were cultured in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% fetal calf serum (FCS, Sigma), 100 U / mL penicillin, 100 μg / mL streptomycin, and 2 mM L-glutamine (all from Gibco) at 37°C and a humidified atmosphere of 5% CO2.

[0387] Therapeutic antibodies

[0388] Anti-CD25 NIB The production of antibodies was outsourced to Evitria AG (Switzerland). Anti-CD25 NIB The antibody is a mouse non-IL-2 blocking anti-CD25 antibody (comprising the variable region of clone 7D4 in a mouse IgG2a backbone, as described in Solomon I et al (2020) Nature Cancer, vol 1, p1153-1166, WO2018 / 167104).

[0389] Isotype control antibody (InVivoMAb polyclonal Armenian hamster IgG) (Cat. #BE0091) and anti-FasL antibody (MFL3) (Cat. #BE0319) were purchased from BioXcell.

[0390] In vivo tumor experiments

[0391] On day 0, 50,000 B16 / BL6 melanoma cells were injected subcutaneously (sc) into the right flank of C57BL / 6 mice. On day 5, 200 μg of anti-CD25 NIB Antibodies. On days 6, 9, and 12 after tumor inoculation, 1×10 6 irradiated (150 Gy) GVAX cells.

[0392] Tumor dimensions were carefully measured 3-4 times per week and volume was calculated as the product of three orthogonal diameters. Tumor volume (mm 3 ) Tumor growth curves were plotted against days after inoculation.

[0393] Tumor growth is closely monitored after initial combination therapy. Only tumors that respond to initial combination therapy are enrolled in further treatment.

[0394] Isotype control antibody (200ug, ip) and anti-FasL (MFL3) mAb (200μg, ip) were given on day 28, when most tumors shrank or remained stable in size. A second dose (also 200μg, ip) was given one week later. In the combination treatment group, anti-CD25 was given on days 25 and 35. NIB (200 μg, ip) to maintain Treg depletion.

[0395] In summary, the treatment groups were as follows:

[0396] Group 1: Day 5, 200 μg anti-CD25 NIB ; Days 6, 9, and 12, 1 × 10 6 GVAX cells; on days 28 and 36, 200 μg isotype control ( Figure 1 A).

[0397] Group 2: Day 5, 200 μg anti-CD25 NIB ; Days 6, 9, and 12, 1 × 10 6 GVAX cells; on days 28 and 36, 200 μg of anti-FasL antibody ( Figure 1 B).

[0398] Group 3: Day 5, 200 μg anti-CD25 NIB ; Days 6, 9, and 12, 1 × 10 6 GVAX cells; 200 μg anti-CD25 on days 11, 17, and 24 NIB ; then once a week until day 56 ( Figure 1 C).

[0399] Group 4: Day 5, 200 μg anti-CD25 NIB ; Days 6, 9, and 12, 1 × 10 6 GVAX cells; on days 25 and 36, 200 μg anti-CD25 NIB ; On days 28 and 36, 200 μg anti-FasL antibody ( Figure 1 D).

[0400] Tumor size was measured 2-3 times per week. Mice were euthanized when any diameter reached 150 mm.

[0401] result

[0402] Figure 2 and Figure 3Results are shown for tumor growth and survival over time. These results indicate that treatment with anti-FasL antibody in combination with anti-CD25 antibody significantly prevented tumor growth recurrence and improved survival.

[0403] Specifically, these experiments showed that adding a combination of anti-FasL antibody and anti-CD25 antibody to an initial combination therapy of anti-CD25 antibody and GVAX prevented tumor growth recurrence and improved survival compared to isotype control, anti-FasL antibody treatment alone, and anti-CD25 antibody treatment alone.

[0404] Because active Teff decreases and Treg increases over time, the use of enhanced treatment regimens (multiple cycles of anti-FasL antibody and anti-CD25 antibody combined treatment) to treat stable tumors is thought to provide more antigen-specific T cells and maintain low Treg counts in the TME, thereby preventing relapse. It is believed that anti-FasL antibodies block the Fas / FasL axis and inhibit Fas-mediated death of activated Teff cells. This inhibition of Fas-mediated death of activated Teffs cells, combined with Treg depletion, helps maintain an immunogenic TME, thereby achieving better therapeutic effects.

[0405] All publications mentioned in the above description are incorporated herein by reference. It will be apparent to those skilled in the art that various modifications and variations of the purposes and methods of the present invention will be made without departing from the scope and spirit of the present invention. Although the present invention has been described in conjunction with specific preferred embodiments, it will be appreciated that the claimed invention should not be unduly limited to such specific embodiments. In fact, it will be apparent to those skilled in the art of molecular biology, cellular immunology or related fields that various modifications to the modes of implementing the present invention will be made, and these modifications are intended to fall within the scope of the following claims.

[0406] The following table provides a summary of the sequences cited in this application:

[0407] Table 2:

[0408]

[0409]

[0410]

[0411]

[0412]

[0413]

Claims

1. A combination of a Treg cell depletion therapy and a Fas axis antagonist for use in treating cancer, wherein the Treg cell depletion therapy and the Fas axis antagonist are administered separately, simultaneously or sequentially.

2. The combination for use according to claim 1, wherein the Treg cell depletion therapy comprises an anti-CD25 antibody.

3. The combination for use according to claim 1 or 2, further comprising a cancer vaccine.

4. The combination for use according to claim 3, wherein the combination comprises: a) a first component comprising the anti-CD25 antibody; b) a second component comprising the Fas axis antagonist; and c) comprising a third component of the cancer vaccine, wherein the first component, the second component and the third component are administered separately, simultaneously or sequentially.

5. The combination for use according to claim 4, wherein the Fas axis antagonist is administered after the anti-CD25 antibody and the cancer vaccine.

6. The combination for use according to any one of claims 4 to 5, wherein the Fas axis antagonist is administered after depletion of Treg cells in the subject by administration of the anti-CD25 antibody.

7. The combination for use according to any one of claims 4 to 6, wherein the anti-CD25 antibody is administered to the subject, followed by the cancer vaccine, and then by the Fas axis antagonist.

8. The combination for use according to any one of claims 4 to 7, wherein the treatment comprises administering multiple doses of the anti-CD25 antibody.

9. The combination for use according to any one of claims 4 to 8, wherein the treatment comprises administering multiple doses of the Fas axis antagonist.

10. The combination for use according to any one of claims 4 to 9, wherein the treatment comprises administering multiple doses of the cancer vaccine.

11. The combination for use according to any one of claims 8 to 10, wherein the administration comprises: - first administering the anti-CD25 antibody; - subsequently administering one or more doses of said cancer vaccine; - subsequently administering one or more alternating administrations of said anti-CD25 antibody and said Fas axis antagonist, wherein each further administration of said anti-CD25 antibody is administered prior to an administration of said Fas axis antagonist.

12. The combination for use according to claim 11, wherein the combination of administration of the Fas axis antagonist and further administration of the anti-CD25 antibody is administered repeatedly over a treatment cycle of at least 7 days.

13. The combination for use according to any one of claims 11 or 12, wherein administering one or more alternating administrations of the anti-CD25 antibody and the Fas axis antagonist further comprises administering one or more administrations of the cancer vaccine, wherein each further administration of the anti-CD25 antibody and the cancer vaccine is administered prior to the administration of the Fas axis antagonist.

14. The combination for use according to any one of claims 4 to 13, wherein the anti-CD25 antibody inhibits IL-2 signalling through CD25 by less than 50% compared to IL-2 signalling in the absence of the antibody.

15. The combination for use according to any one of claims 4 to 14, wherein the cancer vaccine is a cellular immunotherapy expressing cytokines.

16. The combination for use according to claim 15, wherein the cytokine-expressing cellular immunotherapy comprises tumor cells expressing GM-CSF.

17. The combination for use according to any one of claims 1 to 16, wherein the Fas axis antagonist is an anti-FasL antibody.

18. The combination for use according to any one of claims 1 to 17, wherein the cancer is a solid tumor.

19. A kit for treating cancer, comprising: a) a first composition comprising a Treg cell depletion therapy; b) a second composition comprising a Fas axis antagonist, and optional instructions for use in combination therapy.

20. The kit of claim 19, wherein the kit further comprises c) a third composition comprising a cancer vaccine.